FDA nod for generic Lialda launch to boost US biz for Zydus Cadila in FY18

Market for the drug, which could be a key growth driver for firm's US business, is pegged at $1.1 bn

Ahmedabad-headquartered pharma major Zydus Cadila has got the final nod from the US drug regulator to market Mesalamine tablets in the US. The ulcerative colitis drug is estimated to have a market size of $1.145 billion.

While most pharma majors are witnessing degrowth in the US, Zydus Cadila (or Cadila Healthcare) has managed to post a 2.5 per cent rise in its US revenues to Rs 985 crore during the fourth quarter of FY17. Analysts feel the launch of this blockbuster drug that has limited competition is will further boost its US business in FY18. Angel Broking estimated the company